More than 20 per cent of the population suffers from hayfever, making it the most common health condition in the UK.
Hayfever is principally an allergic reaction to pollen, but can be triggered by other allergens such as dust mites, animal saliva, and skin particles.
For those who have succumbed to sniffles and sneezing, the end of grass pollen season could not come soon enough.
Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.